• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Genmab

edit

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options.

Milestones

edit

• 
  Genmab received $134M in Unattributed funding. (7/1/10)
  Posted 7/1/10 at 6:03pm via fiercebiotech.com
• 
  Genmab received $23M in Unattributed funding. (10/1/09)
  Posted 10/27/09 at 11:29pm via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. Genmab wins $23M on blockbuster cancer approval (fiercebiotech.com) [edit]
2. Genmab grabs $134M as it restructures blockbuster GSK pact Read more: Genmab grabs $134M as it restructures blockbuster GSK pact (fiercebiotech.com) [edit]